COVID Breakfast

C

We havent had this for a long while, a bit of light hearted COVID-news whilst you eat your frosties, corn flakes or special K and it may not be MS, But in case you fancy 10 days at home get some…..Lipsmacking, thirst-quenching, acetasting, motivating, cockup-making, good, buzzing cool, walking high, living, evergiving, cool fizzing…COVID-19 test destroying pop

I really hope that we can soon move on from research rubbish like this, but I thought it may help next time you want ten days off school 🙂

Soft drinks can be misused to give false false positive SARS-CoV-2 lateral flow device results Oni, L., Hawcutt, D., Buchan, I., Semple, M. G.10.1101/2021.07.05.21260003 — Posted: 2021-07-

Background The COVID-19 pandemic created the need for very large scale, rapid testing to prevent and contain transmission of the SARS-CoV-2 virus. Lateral flow device (LFD) immunoassays meet this need by indicating the presence of SARS-CoV-2 antigen from nose/throat swab washings in 30 minutes without laboratory processing, and can be manufactured quickly at low cost. Since March 2021, UK schools have asked pupils without symptoms to test twice weekly. Pupils have posted on social media about using soft drinks to create positive results. The aim of this study was to systematically test a variety soft drinks to determine whether they can cause false false positive LFD results. Methods This study used 14 soft drinks and 4 artificial sweeteners to determine the outcome of misusing them as analyte for the Innova SARS-CoV-2 antigen rapid qualitative LFD. The pH value, sugar content and ingredients of each sample are described. The LFD results were double read and a subset was repeated using the same devices and fake analytes but differently sourced. Findings One sample (1/14; 7%), spring water, produced a negative result. Ten drinks (10/14; 71%) produced a positive or weakly positive result. Three samples (3/14; 21%) produced void results, mostly the fruit concentrate drinks. There was no apparent correlation between the pH value (pH 5.0 in 13/14, 93%; pH 6.5 in 1/14; 7%) or the sugar content (range 0-10.7 grams per 100mls) of the drinks and their LFD result. The 4 artificial sweeteners all produced negative results. A subset of the results was fully replicated with differently sourced materials. Interpretation Several soft drinks can be misused to give false positive SARS-CoV-2 LFD results. Daily LFD testing should be performed first thing in the morning, prior to the consumption of any food or drinks, and supervised where feasible. Funding This work was self-funded by author LO and the LFD were gifted for use in this study.

And

A nationwide study of Chlamydia trachomatis infections in Denmark during the COVID-19 pandemicHedley, P. L., Hoffmann, S., Lausten-Thomsen, U., Voldstedlund, M., Bjerre, K. D., Hviid, A., Krebs, L., Jensen, J. S., Christiansen, M.10.1101/2021.06.30.21259819. “Altogether the Danish COVID-19 restrictions have had negligible effects on laboratory confirmed C. trachomatis transmission.”

We should behave no differently and the same welcome to our Danish Visitors today..Best of Luck to Both Teams

and finally some news that may be relevent to MS, not only because of the concern of astrazeneca and clotting, but the fact that the zeneca does not give as high a vacine response as the RNA vaccines, there may be a switch to another vaccine for the boost. Below it shows a pick and mix approach to vaccination is safe and it seems to be even better than getting the same one

Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNATenbusch, M., Schumacher, S., Vogel, E., Priller, A., Held, J., Steininger, P., Beileke, S., Irrgang, P., Brockhoff, R., Salmanton-Garcia, J., Tinnefeld, K., Mijocevic, H., Schober, K., Bogdan, C., Yazici, S., Knolle, P., Cornely, O. A., Ueberla, K., Protzer, U.10.1101/2021.07.03.21258887 — Posted: 2021-07-06

Administration of a first dose of the COVID-19 vaccine ChAdOx1 nCoV-19 (Vaxzevria®, AstraZeneca) is associated with a certain risk for vaccine-induced immune thrombotic thrombocytopenia. Therefore, several countries have recommended replacing the second dose of ChAdOx1 nCoV-19 with an mRNA-based vaccine as a precautionary measure, although data on safety and efficacy of such heterologous prime-boost regimen are sparse. Therefore, vaccinees, who had received a heterologous vaccination using ChAdOx1 nCoV-19 as prime and BNT162b2 (Comirnaty®, BioNTech-Pfizer) mRNA as boost vaccination were offered SARS-CoV-2 antibody testing to quantify their vaccine-induced neutralizing antibody response. The results were compared to cohorts of healthcare workers or volunteers, who received homologous BNT162b2 or homologous ChAdOx1 nCoV-19 vaccination regimens, respectively. A striking increase of vaccine-induced SARS-CoV-2 neutralizing antibody activity was observed in 229 vaccinees that received a BNT162b2 boost 9 to 12 weeks after ChAdOx1 nCoV-19 prime. In our cohort comprising over 480 individuals, the heterologous vaccination scheme induced significantly higher neutralizing antibody titers than homologous ChAdOx1 nCoV-19 and even than homologous BNT162b2 vaccination. This proves that a single dose of a COVID-19 mRNA vaccine after ChAdOx1 nCoV-19 prime vaccination is sufficient to achieve high neutralizing antibody levels predicting immune protection from SARS-CoV-2 infection, and may even increase vaccine efficacy offering an alternative in a setting of vaccine shortage.

About the author

MouseDoctor

3 comments

  • Apparently the combination lamivudine / zidovudine ( which based on data we know zidovudine targets EBV ) got rejected for the Octopus trial because apparently it had : Limited plausibility outside immunosuppressive mechanism.. Well I am disappointed that this lead to the exclusion of this compound.

    You can see it at the bottom left of the page under the title : Excluded by committee.

    https://jnnp.bmj.com/content/jnnp/92/3/295/F4.large.jpg

    • Remember if you design a horse by commitee you get a camel…all my suggestions were rejected by the commitee

      • Well I see the value in your ideas ( I see the value of this idea that you and Professor Gavin stand for ). It’s a matter of time before your ideas get taken more seriously ( EBV ) and that both industry and the charities fund more trials targeting EBV.

        The ms charity in australia is already funding some of this research. This is one of their EBV studies : Targeting EBV In Immune Cells As a Potential New MS Therapy

        Mr Ali Afrasiabi

        This project aims to test the effects of targeting three important EBV viral genes to reduce the amount of EBV in B cells as well as reducing its ability of the virus to continue hijacking B cells leading to their proliferation.

        https://msra.org.au/project/investigating-ebv-infected-b-cells-to-develop-a-new-ms-therapy/

By MouseDoctor

Translate

Categories

Recent Posts

Recent Comments

Archives